Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying the role of MTHFD1L in prostate cancer progression from genetic analysis and experimental validation

ABSTRACT: Identifying the role of MTHFD1L in prostate cancer progression from genetic analysis and experimental validation

PROVIDER: PRJNA1047159 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27007322_1.fastq.gz	Fastqsanger.gz
	SRR27007322_2.fastq.gz	Fastqsanger.gz
	SRR27007323_1.fastq.gz	Fastqsanger.gz
	SRR27007323_2.fastq.gz	Fastqsanger.gz
	SRR27007324_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Identifying the role of MTHFD1L in prostate cancer progression from genetic analysis and experimental validation

Project description:One-carbon metabolism plays a crucial role in tumorigenesis as it supplies the one-carbon units necessary for nucleotide synthesis, epigenetic regulation, and redox metabolism, ensuring the rapid proliferation of cancer cells. However, their roles in prostate cancer progression remain poorly understood. In this study, we investigated the association between genetic variants in the one-carbon metabolism pathway and clinical outcomes in patients receiving androgen deprivation therapy for prostate cancer. The associations of 130 single-nucleotide polymorphisms located within 14 genes involved in the one-carbon metabolism pathway with cancer-specific survival (CSS), overall survival, and progression-free survival were assessed using Cox regression in 630 patients with prostate cancer. Subsequently, functional studies were performed using prostate cancer cell lines. After adjusting for covariates and multiple testing, MTHFD1L rs2073190 was found to be significantly associated with CSS (P = 0.000184). Further pooled analysis of multiple datasets demonstrated that MTHFD1L was upregulated in prostate cancer and increased MTHFD1L expression was positively correlated with tumor aggressiveness and poor patient prognosis. Functionally, MTHFD1L knockdown suppressed prostate cancer cell proliferation and colony formation. RNA sequencing and pathway analysis revealed that differentially expressed genes were predominantly enriched in the cell cycle pathway. In conclusion, genetic variants in MTHFD1L of one-carbon metabolism may serve as promising predictors, and our findings offer valuable insights into the underlying genetic mechanisms of prostate cancer progression.

2024-02-15 | GSE249098 | GEO

Identifying the role of MTHFD1L in prostate cancer progression from genetic analysis and experimental validation.

| S-EPMC10839318 | biostudies-literature

Computational prediction and experimental validation identify functionally conserved lncRNAs from zebrafish to human

Project description:Computational prediction and experimental validation identify functionally conserved lncRNAs from zebrafish to human

| PRJNA1003409 | ENA

Bojungikki-tang ameliorates psoriasis-like dermatitis: Network analysis and transcriptomics with experimental validation

Project description:Bojungikki-tang ameliorates psoriasis-like dermatitis: Network analysis and transcriptomics with experimental validation

| PRJNA1336304 | ENA

Cycloastragenol inhibit experimental abdominal aortic aneurysm progression

Project description:Abstract: The pathogenesis of AAA involves vascular inflammation and oxidative stress. Astragali Radix contains cycloastragenol (CAG) known to have anti-inflammatory and anti-oxidative properties. We hypothesized that CAG supplement impairs AAA progression. AAA was induced in male rats by intraluminal elastase infusion in the infrarenal aorta and treated daily with CAG (125 mg/kg/day). Aortic expansion was followed weekly by ultrasound, with euthanization at day 28. Changes in AAA wall composition were analyzed at mRNA levels, histology, zymography and explorative proteomic analyses. At day 28, mean AAA diameter was 37% lower in CAG group (p<0.0001). In aneurysm cross sections, elastin content was insignificantly higher in CAG group (10.5% ± 5.9% vs 19.9% ± 16.8%, p=0.20) with more preserved elastin lamellae structures (p=0.0003) and with no microcalcifications. Aneurysmal matrix metalloprotease-2 activity was reduced by CAG treatment (p=0.022), and mRNA levels of inflammatory- and antioxidative markers showed no difference between groups. Explorative proteomic analysis showed no difference in protein levels when adjustment for multiple testing. Amongst unadjusted affected proteins were fibulin-5 (p=0.02), aquaporin-1 (p=0.02) and prostacyclin synthase (p=0.006). CAG impairs experimental AAA progression by reduction of elastin degradation through decreased MMP-2 activity, thus CAG could be considered tested in AAA patients.

2022-05-20 | PXD030441 | Pride

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

Project description:This research trial studies how well biospecimen collection works in identifying genetic changes in patients with breast, prostate, colorectal, liver, or kidney cancer or multiple myeloma undergoing surgery. Studying samples collected during surgery may add to the understanding of cancer by looking for the genetic changes that cause early cancer onset in people of certain racial and ethnic groups.

| 2382834 | ecrin-mdr-crc

Identifying the patients with rapid progression from hormone-sensitive to castration-resistant prostate cancer

Project description:We collected 78 biopsies and analyzed the proteomic expression by pressure cycling technology and Pulsed data-independent acquisition (PCT-PulseDIA) pipeline. Next, we explore the differentially expressed proteins (DEPs) in the discovery set (n=16) which contains short (S, n=8)- and long (L, n=8)- term progression. The progression-related proteins were further identified in another dataset, modeling set (n=62), utilizing the ANOVA estimation and random forest model. Multivariable Cox regression analysis was then conducted to determine clinical and protein variables significantly associated with the progression of HSPC in the whole sample set (n=78).

2022-11-04 | PXD037951 |

Identifying urinary RNA as non-invasive biomarkers for progression of chronic kidney disease

Project description:Identifying urinary RNA as non-invasive biomarkers for progression of chronic kidney disease

| PRJNA501882 | ENA

A critical role for thrombin in regulating chondrocytes catabolism through RNA-Seq and experimental validation

Project description:A critical role for thrombin in regulating chondrocytes catabolism through RNA-Seq and experimental validation

| PRJNA762871 | ENA

Experimental validation of small mammal gut microbiota sampling from faeces and from caecum after death.

Project description:Experimental validation of small mammal gut microbiota sampling from faeces and from caecum after death.

| PRJEB41530 | ENA